RxDoctor Payments Data

Adrian da Silva de Abreu, MD

Cardiovascular Disease · Rochester, MNNPI 1588041222

Payments from drug & device makers

$19,105in general payments, 2019–2025

Across 45 payments — averaging $424.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$16K
  • Abbott$2K
  • AstraZeneca$319
  • Esperion Therapeutics, Inc.$170
  • E.r. Squibb & Sons, L.L.C.$132
  • United Therapeutics Corporation$120
  • plus $119 from 3 others

What the payments were for

  • Grants$16,41487%
  • Travel & lodging$1,2327%
  • Food & beverage$1,0676%
  • Education$1871%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,105 in reported general payments places this provider in the 65th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota

Medicare billing

Part B allowed, 2024
$39,400
Medicare patients
188
Services billed
404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan95$109,200
FarxigaDapagliflozin Propanediol61$53,508
JardianceEmpagliflozin37$28,006
Sirolimus21$23,641
EliquisApixaban27$20,002
Mycophenolate Mofetil55$4,228
Metoprolol Succinate136$2,241
Clonidine19$1,848
Rosuvastatin Calcium144$1,454
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim93$1,064
Eplerenone12$771
Bisoprolol Fumarate34$750
Carvedilol53$691
Losartan Potassium158$657
Spironolactone101$618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$319$53,50861 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 451 cardiovascular disease providers in Minnesota.

Other cardiovascular disease in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →